摘要
目的探讨高龄老年心力衰竭患者应用冻干重组人脑利钠肽(新活素)的疗效及安全性。方法 60例高龄老年心力衰竭患者,随机分为对照组和观察组,每组30例。对照组患者给予心力衰竭标准药物治疗,观察组患者在对照组基础上加用新活素治疗。比较两组患者治疗效果、治疗前后氨基末端脑钠肽前体(NT-proBNP)水平,记录观察组患者不良反应发生情况。结果观察组总有效率为93.33%,高于对照组的73.33%,差异具有统计学意义(P<0.05)。治疗前,观察组NT-proBNP水平为(7286.40±316.53)pg/ml,对照组NT-proBNP水平为(7257.10±301.81)pg/ml;治疗后,观察组NT-proBNP水平为(4574.70±217.79)pg/ml,对照组NT-proBNP水平为(6052.87±337.52)pg/ml。治疗前,两组患者NT-proBNP水平比较差异无统计学意义(P>0.05);治疗后,两组患者NT-proBNP水平均显著低于本组治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组1例患者出现了低血压及头晕症状,不良反应发生率为3.33%(1/30)。结论高龄老年心力衰竭患者应用新活素治疗效果显著,安全性好。
Objective To investigate the efficacy and safety of lyophiluzed recombinant human brain natriuretic peptide in elderly patients with heart failure. Methods 60 elderly patients with heart. failure were randomly divided into the control group and the observation group, 30 cases in each group. The control group was given standard pharmaceutical therapy for heart failure. The observation group was given lyophiluzed recombinant human brain natriuretic peptide on the basis of control group. The treatment effect and the level of N-terminal pro brain natriuretic peptide （NT-proBNP） before and after treatment between the two groups were compared, the occurrence of adverse reactions in the observation group was recorded. Results The effective rate of the observation group was 93.33%, which was significantly higher than 73.33% of the control group, the difference was statistically significant （P〈0.05）. Before treatment, the level of NT-proBNP in the observation group was （7286.40 ± 316.53） pg/ml, that of the control group was （7257.10 ± 301.81） pg/ml, there was no statistically significant difference （P〉0.05）. After treatment, the level of NT-proBNP in the observation group was （4574.70 ± 217.79） pg/ml, that in the control group was （6052.87± 337.52） pg/ml, the level of NT-proBNP of the two groups were significantly lower than before treatment, and that of observation group was significantly lower than control group, the differences were statistically significant （P〈0.05）. In the observation group, 1 case had hypotension and dizziness, the incidence of adverse reactions was 3.33% （1/30）. Conclusion The effect of lyophiluzed recombinant human brain natriuretic peptide in elderly patients with heart failure is significant and safe.
作者
刘洪霞
蒋雪羚
甘晓雅
孙阳
LIU Hong-xia;JIANG Xue-ling;GAN Xiao-ya(Department of Cardiovascular, Taishan Hospital of Shandong Province, Tai＇ an 271000, China)
出处
《中国实用医药》
2018年第19期1-2,共2页
China Practical Medicine
关键词
心力衰竭
冻干重组人脑利钠肽
老年
Heart failure
Lyophiluzed recombinant human brain natriuretic peptide
Elderly
